Lateral flow device for diagnosing microbial infections
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 14, 2019
Grant Date -
Jan 17, 2013
app pub date -
Nov 23, 2010
filing date -
Nov 23, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully